Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist Watchlist | Portfolio Portfolio | Dashboard Dashboard
Hi,
Site News
Contact
Market:
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.
Menu

Madrigal Pharmaceuticals Inc (MDGL)

Madrigal Pharmaceuticals Inc (MDGL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch Watch
Help
Go To:
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu Aug 20, 3:05PM CDT

CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 538.71 (-0.24%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu Aug 20, 3:05PM CDT

CONSHOHOCKEN, Pa., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 538.71 (-0.24%)
Madrigal Appoints John C. Reed, M.D., Ph.D., to its Board of Directors GlobeNewswire - Wed Aug 12, 7:00AM CDT

CONSHOHOCKEN, Pa., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 538.71 (-0.24%)
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Thu Aug 6, 3:05PM CDT

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated...

MDGL : 538.71 (-0.24%)
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference GlobeNewswire - Thu Aug 6, 7:00AM CDT

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in...

MDGL : 538.71 (-0.24%)
Madrigal Pharmaceuticals to Participate in the Canaccord Genuity 45th Annual Growth Conference GlobeNewswire - Thu Aug 6, 7:00AM CDT

CONSHOHOCKEN, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that the company will participate in the Canaccord Genuity 46 th Annual Growth Conference...

MDGL : 538.71 (-0.24%)
Madrigal: Q2 Earnings Snapshot AP - Thu Jul 30, 6:11AM CDT

Madrigal: Q2 Earnings Snapshot

MDGL : 538.71 (-0.24%)
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates GlobeNewswire - Thu Jul 30, 6:00AM CDT

Second-quarter 2026 Rezdiffra ® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more...

MDGL : 538.71 (-0.24%)
Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates GlobeNewswire - Thu Jul 30, 6:00AM CDT

Second-quarter 2026 Rezdiffra® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000...

MDGL : 538.71 (-0.24%)
Madrigal's Rezdiffra Revenue Momentum May Already Be Reflecting a Best-Case Scenario That Hasn't Arrived Barchart - Wed Jul 29, 4:16PM CDT

Barchart Research What to Expect from MDGL Earnings MDGL Generated July 29, 2026 Current Price $546.88 EPS Estimate $$-2.55 Consensus Rating Strong Buy Average Move 10.51% Madrigal's Rezdiffra Revenue...

MDGL : 538.71 (-0.24%)

Barchart Exclusives

Dear Amphenol Stock Fans, Mark Your Calendars for September 2 Barchart - 24 minutes ago
Amphenol is splitting its stock just as its AI-fueled growth story heats up, giving investors another reason to watch this data-center connectivity powerhouse. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.